All News

Pivotal phase 3 trial results show benefits for once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; Trelegy Ellipta) in patients with uncontrolled asthma compared with standard FF/VI (Breo Ellipta) therapy.

In the first and largest study of its kind, researchers from the University of British Columbia (UBC) and Vancouver Coastal Health Research Institute aimed to assess mortality associated with beta interferons for the treatment of MS.

The FDA rapidly reviewed and approved Genentech’s application under the FDA’s Real-Time Oncology Review (RTOR) and Assessment Aid pilot programs, leading to an approval 12 weeks after completing the submission.

Officials with the FDA have approved AstraZeneca’s dapagliflozin, saxagliptin and metformin hydrochloride (Qternmet XR) extended release tablets for adults with type 2 diabetes.

Results of the recent study, published in The Lancet, support the benefits of early testing and treatment for HIV, as well as the message of Prevention Access Campaign’s U=U (undetectable equals untransmittable) initiative.

A molecular switch in the skin cells may cause increased susceptibility to autoimmunity in women.

Measles cases are increasing at an alarming rate, and the antivaccination movement has helped bring back this potentially deadly disease that was once eliminated in the United States.

Teva Pharmaceutical Industries has launched a generic version of Gilead’s Letairis (ambrisentan) Tablets, 5 mg and 10 mg, in the United States.

The approved generic treatment is therapeutically equivalent to Novartis’ Pataday Ophthalmic Solution, 0.2%, according to Alembic.

The sNDA was granted Priority Review and accepted under the agency's Real-Time Oncology Review pilot program, which aims to make the review of oncology drugs more efficient by allowing the FDA access to clinical trial data before the information is formally submitted to the agency.

The influenza vaccine for the 2019-2020 flu season will look different than it has for the past few seasons.

The study authors believe that the modification of teriflunomide and the development of new DHODH inhibitors is urgent for drug-resistant epilepsy patients

Using medications to induce calm is generally considered less desirable than other methods of de-escalation but is often necessary to prevent injury.

Patients taking beta interferons for at least 6 months had a reduced mortality risk compared with patients who did not take the drug.

The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.

Top news of the week from Specialty Pharmacy Times.

Dengue is endemic in the United States territories of American Samoa, Guam, Puerto Rico and the US Virgin Islands.

The study authors believe that the modification of teriflunomide and the development of new DHODH inhibitors is urgent for drug-resistant epilepsy patients

Partnerships like the UC College of Pharmacy and Walgreens offer opportunities for experience with complex disease states, such as cancer, multiple sclerosis, HIV, and Crohn’s disease, that many students will see after they graduate.

A number of landmark clinical studies on lipid lowering and cardiovascular health have been published, shaping how patients are treated.

As highly accessible health care professionals, pharmacists have the opportunity to improve medication adherence and health outcomes of patients with bipolar disorder.

Mouthwash containing diphenhydramine, lidocaine, and antacids found to significantly reduce pain from oral mucositis in patients with head and neck cancer administered chemotherapy.

"If successful, this has the potential to contribute to a cure for HIV."

The FDA's boxed warning requirement follows several reports of rare, but serious injuries and deaths resulting from various complex sleep behaviors after taking these medicines.

The best natural supplements become drugs.

This drug was previously approved, in 2017, to treat HCV in adults.

The preclinical data was presented by Beam Therapeutics, Monday at the American Society of Gene and Cell Therapy (ASGCT) 22nd Annual Meeting in Washington, DC.

The organization awarded the title to these heath care professions in recognition of the excellence achieved in pharmacy practice, according to the organization.